MORGAN STANLEY PLC/CALL/NOVO NORDISK ADR B/210/0.1/16.01.26 Stock

Warrant

DE000MG5D2D8

Real-time Bid/Ask 11:48:19 2024-07-01 EDT
0.88 EUR / 0.89 EUR +6.63% Intraday chart for MORGAN STANLEY PLC/CALL/NOVO NORDISK ADR B/210/0.1/16.01.26
Date Price Change
24-07-01 0.89 +7.23%
24-06-28 0.83 -2.35%
24-06-27 0.85 -1.16%
24-06-26 0.86 -9.47%
24-06-25 0.95 +20.25%

Delayed Quote Börse Stuttgart

Last update July 01, 2024 at 11:34 am

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying NOVO NORDISK A/S
Issuer Morgan Stanley
WKN MG5D2D
ISINDE000MG5D2D8
Date issued 2024-06-06
Strike 210 $
Maturity 2026-01-16 (564 Days)
Parity 10 : 1
Emission price 0.82
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 0.95
Lowest since issue 0.77
Spread 0.01
Spread %1.14%

Company Profile

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
More about the company

Ratings for Novo Nordisk A/S

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Consensus: Novo Nordisk A/S

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,006 DKK
Average target price
949.7 DKK
Spread / Average Target
-5.56%
Consensus